Photodynamic therapy: current role in the treatment of chorioretinal conditions.
Eye (Lond)
; 30(2): 202-10, 2016 Feb.
Article
em En
| MEDLINE
| ID: mdl-26742867
ABSTRACT
Verteporfin photodynamic therapy (vPDT) is a selective vaso-occlusive treatment that targets choroidal vascular abnormalities. It was initially developed to treat neovascular age-related macular degeneration using the 'standard' vPDT protocol (verteporfin 6 mg/m(2), vPDT laser fluence 50 J/cm(2)). vPDT therapy has subsequently evolved as an important treatment modality for a range of other chorioretinal conditions including choroidal haemangioma, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and peripapillary choroidal neovascularisation. Various 'safety-enhanced' vPDT protocols have been devised to optimise treatment outcomes, typically using reduced dose verteporfin (verteporfin 3 mg/m(2)) or reduced fluence vPDT (vPDT laser fluence 25 J/cm(2)). This paper reviews the current role of vPDT therapy in the treatment of chorioretinal conditions.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fotoquimioterapia
/
Porfirinas
/
Doenças Retinianas
/
Doenças da Coroide
/
Fármacos Fotossensibilizantes
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Eye (Lond)
Ano de publicação:
2016
Tipo de documento:
Article